Application of remdesivir in preparation of medicine for treating diabetic complications

A technology for complications and diabetes, applied in drug delivery, drug combination, urinary system diseases, etc., to achieve the effect of improving application potential, market prospect and good curative effect

Active Publication Date: 2021-04-09
北京箭牧科技有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no clinically effective drug to treat this disease, and it is urgent to develop new drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of remdesivir in preparation of medicine for treating diabetic complications
  • Application of remdesivir in preparation of medicine for treating diabetic complications
  • Application of remdesivir in preparation of medicine for treating diabetic complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 db / db diabetes mouse model successfully constructed

[0028] Experimental Materials

[0029] Experimental animals: db / db diabetic mouse model, 8 weeks old, SPF grade, male, provided by Beijing Huafukang Animal Experiment Co., Ltd.

[0030] Blood glucose test strips: purchased from Roche Diagnostic Products (Shanghai) Co., Ltd.

[0031] 2. Experimental steps

[0032] 1. Select 7-week-old db / db male mice to perform adaptive feeding for 1 week, then conduct blood glucose testing experiments, measure fasting blood glucose and random blood glucose, and confirm that the mouse model is successfully constructed, and the phenotype of elevated blood glucose appears. Littermates of normal genotype BKS mice were selected as the negative control group.

[0033] 2. Select db / db male mice aged 12-15 weeks and their littermate normal genotype BKS mice, and take blood from the orbits to measure the changes in blood glucose, blood lipids, and renal function indicators of the...

Embodiment 2

[0046] Example 2 Remdesivir has a protective therapeutic effect on the kidneys of diabetic nephropathy mice

[0047] 1. Experimental materials

[0048] 1. Remdesivir: Protect from light, seal, and dry at 4°C. Take an appropriate amount of medicine, dissolve it in 0.5% sodium carboxymethylcellulose, and make it 8mg / mL (relative to 80mg / kg). The 8mg / mL solution was diluted serially. Each animal was orally given 0.2mL / 20g by gavage according to body weight. Ready to use.

[0049] 2. Solvent: 0.5% sodium carboxymethylcellulose (CMC).

[0050] 3. Positive control drug: metformin hydrochloride.

[0051] All the other are with embodiment 1.

[0052] 2. Experimental group

[0053] a) Control group (negative control): BKS mice

[0054] b) Model group (db / db mice) + solvent

[0055] c) Model group (db / db mice) + remdesivir (10mg / kg, po, QD)

[0056] d) Model group (db / db mice) + remdesivir (20mg / kg, po, QD)

[0057] e) Model group (db / db mice) + remdesivir (40mg / kg, po, QD) ...

Embodiment 3

[0070] Example 3 Remdesivir has a therapeutic effect on cardiovascular complications in diabetic mice

[0071] 1. Experimental materials

[0072] All the other are with embodiment 2.

[0073] 2. Experimental group

[0074] a) Control group (negative control): BKS mice

[0075] b) Model group (db / db mice) + solvent

[0076] c) Model group (db / db mice) + remdesivir (10mg / kg, po, QD)

[0077] d) Model group (db / db mice) + remdesivir (20mg / kg, po, QD)

[0078] e) Model group (db / db mice) + remdesivir (40mg / kg, po, QD)

[0079] f) Positive control: model group (db / db mice) + metformin hydrochloride (300mg / kg / d, po, QD)

[0080] po: oral administration, QD: once a day.

[0081] 3. Experimental steps

[0082] With embodiment 2.

[0083] 4. Experimental results and conclusions

[0084] The pathological mechanism of diabetic cardiovascular complications includes atherosclerosis, and dyslipidemia is an important risk factor.

[0085] Figure 5 It is the detection and analysi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of remdesivir in preparation of a medicine for treating diabetic complications, especially diabetic nephropathy and cardiovascular complications. According to the invention, the great potential of the remdesivir as the medicine for preventing and treating the diabetic nephropathy and cardiovascular complications is proved, a good curative effect of the remdesivir on various complications caused by diabetes is disclosed for the first time, an effective novel potential alternative medicine is provided for treating the diabetic nephropathy and other complications, the indications of the remdesivir are expanded, and the application potential and the market prospect of the remdesivir are greatly improved.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to the application of remdesivir in diabetic complications, especially diabetic nephropathy and diabetic cardiovascular complications. Background technique [0002] Remdesivir (RDV, GS-5734) is a nucleoside analog antiviral drug developed by Gilead Sciences (GILD) that works by inhibiting viral nucleic acid synthesis. [0003] In the patent WO2009132123A1, the general formula of the compound structure of Remdesivir was proposed for the first time, which is used for the treatment of hepatitis C virus infection, dengue fever and other flaviviridae virus infection diseases. Patent WO2012012776A1 proposes the effect of Remdesivir in treating diseases infected by Paramyxoviridae viruses. In subsequent patents, it is also proposed that RDV can be used as an anti-filovirus, anti-arenavirus and anti-coronavirus drug. According to literature information, the anti-tumor effect of remdesiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/685A61K9/00A61P3/10A61P13/12A61P9/10A61P9/12A61P3/06
CPCA61K31/685A61K9/0053A61K9/0019A61P3/10A61P13/12A61P9/10A61P9/12A61P3/06
Inventor 崔庆华周宛露
Owner 北京箭牧科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap